Daiichi Sankyo Company, Limited (TYO:4568)
Japan · Delayed Price · Currency is JPY 2,799.50
+44.50 (1.62%)
Jul 24, 2026, 3:30 PM JST
Daiichi Sankyo Company Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Revenue Revenue Growth | 2,123,045 | 2,123,045 | 1,886,256 | 1,601,688 | 1,278,478 | 1,044,892 |
Revenue Growth | 12.55% | 12.55% | 17.77% | 25.28% | 22.36% | 8.56% |
Gross Profit Gross Profit Growth | 1,454,000 | 1,454,000 | 1,470,459 | 1,186,366 | 914,953 | 691,564 |
Operating Income Operating Income Growth | 212,585 | 212,585 | 311,924 | 211,483 | 101,928 | 73,027 |
Net Income Net Income Growth | 259,874 | 259,874 | 295,756 | 200,731 | 109,188 | 66,972 |
Earnings Per Share EPS Growth | 140.37 | 140.37 | 155.87 | 104.62 | 56.91 | 34.91 |
EPS Growth | -9.94% | -9.94% | 48.99% | 83.83% | 63.02% | -10.74% |
| Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Prescription Drugs Prescription Drugs Growth | 2,029,538 | 1,796,974 | 1,523,410 | 1,205,939 | 977,984 |
Healthcare (OTC) Products Healthcare (OTC) Products Growth | 90,784 | 86,587 | 75,895 | 70,331 | 64,703 |
Other Other Growth | 2,722 | 2,693 | 2,382 | 2,207 | 2,204 |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Investments Cash & Investments Growth | 449,807 | 449,807 | 639,838 | 647,180 | 441,921 | 662,477 |
Total Debt Total Debt Growth | 350,051 | 350,051 | 155,890 | 156,001 | 192,855 | 213,615 |
Net Cash (Debt) Net Cash Growth | 99,756 | 99,756 | 483,948 | 491,179 | 249,066 | 448,862 |
Net Cash Growth | -79.39% | -79.39% | -1.47% | 97.21% | -44.51% | 190.76% |
Net Cash Per Share Net Cash Per Share Growth | 53.88 | 53.88 | 255.05 | 256.00 | 129.82 | 233.97 |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 77,655 | 77,655 | 53,842 | 599,258 | 114,514 | 139,226 |
Capital Expenditures CapEx Growth | -128,365 | -128,365 | -116,259 | -88,321 | -60,749 | -62,736 |
Free Cash Flow Free Cash Flow Growth | -50,710 | -50,710 | -62,417 | 510,937 | 53,765 | 76,490 |
Free Cash Flow Growth | - | - | - | 850.31% | -29.71% | -52.48% |
| Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Gross Margin | 68.49% | 68.49% | 77.96% | 74.07% | 71.57% | 66.19% |
Operating Margin | 10.01% | 10.01% | 16.54% | 13.20% | 7.97% | 6.99% |
Pretax Margin | 12.41% | 12.41% | 18.85% | 14.81% | 9.92% | 7.04% |
Profit Margin | 12.24% | 12.24% | 15.68% | 12.53% | 8.54% | 6.41% |
FCF Margin | -2.39% | -2.39% | -3.31% | 31.90% | 4.21% | 7.32% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Dividend Per Share Dividend Per Share Growth | 100.000 | 78.000 | 60.000 | 50.000 | 30.000 | 27.000 |
Dividend Per Share Growth | 30.00% | 30.00% | 20.00% | 66.67% | 11.11% | 0% |
Dividend Yield | 3.57% | 2.82% | 1.75% | 1.09% | 0.65% | 1.07% |
| Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 26, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 19.94 | 19.52 | 22.29 | 45.63 | 84.67 | 76.70 |
Forward PE | 17.71 | 13.38 | 25.59 | 49.66 | 66.86 | 152.23 |
P/FCF Ratio | - | - | - | 17.93 | 171.94 | 67.16 |
PS Ratio | 2.36 | 2.39 | 3.49 | 5.72 | 7.23 | 4.92 |